Medivation, Astellas look to widen use of Xtandi cancer drug


Medivation (MDVN +2% premarket) and Astellas Pharma (ALPMF) have filed a request with the FDA to widen the use of their Xtandi product to treat men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy.

Xtandi is already approved for the treatment of patients with mCRPC who have received Docetaxel chemotherapy.

The companies intend to file a similar request in the EU later this year. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs